At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
BroadwayWorld1d
Goethe-Institut Boston Announces Its Next Studio 170 Artist Residency
Multimedia artist Ngoc-Tran Vu, one of two Studio 170 artists-in-resident in 2025, develops and presents a body of work that experiments with ideas to build toward her project 'Journey of Light: A ...
Philippine Daily Inquirer1d
FDA OKs painkiller designed to cut opioids-linked addiction risk
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
Engineering News-Record1d
Boston Approves First in the Nation Net Zero Carbon Rule
Boston’s first in the-nation net zero carbon zoning rule for new buildings passed Jan. 29 after failing to gain enough votes ...
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
AFP2d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
AFP2d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...